Advanced Pediatric Oncology Drugs

More than 100 drugs have been approved by the Division of Oncology Drug Products of the FDA for the treatment of malignancies. Only 15 have pediatric use information in their labeling, which is less than 50% of the drugs commonly used in the treatment of pediatric malignancies. In the past 20 years, there have been six submissions to the FDA for pediatric oncology indications.

Pediatric oncology is particularly susceptible to drug shortages, presenting an opportunity to examine these ethical issues and provide recommendations for preventing and alleviating shortages.

More than 100 drugs have been approved by the Division of Oncology Drug Products of the FDA for the treatment of malignancies. Only 15 have pediatric use information in their labeling, which is less than 50% of the drugs commonly used in the treatment of pediatric malignancies. In the past 20 years, there have been six submissions to the FDA for pediatric oncology indications.

  • Advancement in Chemotherapy
  • Efficacy of drugs used on Pediatric
  • Treatment strategies using Drugs
  • Adverse effects of drugs
  • Advances in Ongoing clinical trails

Related Conference of Advanced Pediatric Oncology Drugs

Advanced Pediatric Oncology Drugs Conference Speakers